Best Oral GLP-1 Tablet & ODT Providers in 2026 — Ranked & Reviewed
Most compounded GLP-1 providers ship injectable vials, but a growing minority offer oral formulations — sublingual tablets, oral dissolving tablets (ODT), or other non-injectable delivery. The clinical evidence for oral compounded GLP-1s is weaker than for the FDA-approved injectable equivalents (no STEP-or-SURMOUNT-equivalent randomized trials of oral compounded semaglutide or tirzepatide), and the only FDA-approved oral GLP-1 for weight loss is Lilly's Foundayo (orforglipron), which is a completely different small-molecule chemistry. That said, ODTs and oral tablets are a reasonable option for needle-averse patients willing to accept the weaker evidence base. Below we rank every provider in our directory offering an oral compounded GLP-1 alongside or instead of injectable versions, with explicit notes on form factor and evidence quality.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 5
Detailed Reviews
Amazon One Medical
Best for: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings
Amazon One Medical is the unified Amazon GLP-1 channel — One Medical clinicians prescribe FDA-approved Wegovy, Zepbound, and Foundayo (no compounded products), and Amazon Pharmacy fulfills with same-day delivery across roughly 3,000 US cities plus pickup kiosks at select One Medical locations. No prior membership required; insurance and cash pay both accepted. Foundayo launched at $25/month with insurance and the Lilly Savings Card, or $149/month cash pay.
Score Breakdown
Pros
- ✓As low as $1/day ($25/month) for brand-name Foundayo with insurance and the auto-applied Lilly coupon
- ✓Same-day delivery in nearly 3,000 US cities at launch, expanding to 4,500 by end of 2026
- ✓In-office pharmacist kiosks at select One Medical clinics let you walk out with Foundayo in hand
- ✓Cash-pay $5/day ($149/month) is competitive for the same FDA-approved brand-name product
- ✓Real-time availability, transparent pricing, and automatic manufacturer coupon at checkout
- ✓Delivering GLP-1 medications since 2021 — track record on cold-chain logistics
Cons
- ✗Headline $25/month needs both insurance and the Lilly Savings Card — uninsured pay $149/month
- ✗Same-day delivery is geographically gated; outside major cities it drops to next-day or slower
- ✗Pricing is set by manufacturer savings programs and can change at any time
- ✗No compounded options — brand-name only (Foundayo, Wegovy, Zepbound)
- ✗Wegovy/Zepbound pricing isn't shown upfront — depends on insurance at the prescribing visit
- ✗Copays and deductibles still apply to the clinical visit
LillyDirect Foundayo
Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
Score Breakdown
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Cons
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
Embody
Verified partnerBest for: lowest first-month entry pricing on compounded GLP-1s
Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation. Aggressive first-month entry pricing with all 50 states and a 24/7 clinician messaging model led by a board-certified internal medicine CMO.
Score Breakdown
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
GoodRx
Best for: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Offers self-pay discount pricing for brand-name GLP-1 medications — Foundayo (orforglipron) starting at $149/month and Zepbound KwikPen (tirzepatide) starting at $299/month — redeemable at 70,000+ pharmacies nationwide. Also operates GoodRx Care, a telehealth arm offering GLP-1 prescriptions with online visits starting at $39.
Score Breakdown
Pros
- ✓$149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- ✓$299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- ✓Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- ✓No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded
- ✓Manufacturer-direct pricing — Lilly delivers the discount through GoodRx, not a third-party negotiation
- ✓GoodRx Care telehealth offers GLP-1 prescriptions ($39–$70 per visit, $19 with Gold) — one-stop for script plus card
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- ✗Self-pay only — does not apply toward insurance benefits or deductibles
- ✗Headline price applies to the lowest Foundayo dose; higher doses may cost more
- ✗No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- ✗Pricing can change as Lilly's manufacturer coupon program evolves
YourHealthRx
Best for: Science-forward GLP-1 and peptide care nationwide, with flat-rate dosing and built-in clinical follow-up
YourHealthRx is a scientist-founded peptide and GLP-1 telehealth platform available in all 50 states and DC via a multi-state (IMLC) clinician network. Compounded semaglutide and tirzepatide come as a weekly injectable (with B12) or a daily oral tablet, at a flat subscription price that doesn't change with your dose - injectable semaglutide ~$170/mo and tirzepatide ~$210/mo ongoing. It also offers a broad peptide catalog plus lab testing. Prescribing runs through partner clinical workflows; compounded meds aren't FDA-approved, the pharmacy isn't named, and no LegitScript is shown.
Score Breakdown
Pros
- ✓Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
- ✓Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
- ✓Flat subscription price that doesn't change as your dose increases (no titration penalty)
- ✓Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
- ✓Transparent, education-first positioning with published medical disclaimer, privacy, and terms
Cons
- ✗Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
- ✗Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- ✗The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
- ✗Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
- ✗No LegitScript certification displayed
Related Rankings
Frequently Asked Questions
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.